US04546C2052 - Common Stock
NASDAQ:ASRT (3/28/2023, 8:48:05 AM)+0.11 (+1.75%)
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients utilizing a non-personal promotional model. The Company’s commercial portfolio of branded products focuses on three areas: neurology, rheumatology, and pain and inflammation. Its primary marketed products include INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Otrexup (methotrexate) injection for subcutaneous use, Sympazan (clobazam) oral film, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipso (diclofenac potassium) Liquid filled capsules. Its other commercially available products include OXAYDO (oxycodone HCI, USP) tablets for oral use. INDOCIN (indomethacin) Suppositories are nonsteroidal anti-inflammatory drug (NSAID), indicated for moderate to severe rheumatoid arthritis, including acute flares of chronic diseases, moderate to severe ankylosing spondylitis, acute gouty arthritis and others.
ASSERTIO HOLDINGS INC
100 S. Saunders Road, Suite 300
Lake Forest ILLINOIS 60045
CEO: Daniel A. Peisert
Assertio Therapeutics press release (ASRT): Q4 Non-GAAP EPS of $0.32 beats by $0.12.Revenue of $50.35M (+51.1% Y/Y) beats by $2.91M.Adjusted EBITDA increased to $33.4 million,...
Net Product Sales Increase 55% in the Fourth Quarter, 42% for the Full Year Full Year Net Income Increases to $109.6 Million, Non-GAAP Adjusted EBITDA...
LAKE FOREST, Ill., March 06, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical...
Sometimes you need to be aggressive to unlock the best returns for your portfolio. Just be smart when looking for the best stocks to buy.
LAKE FOREST, Ill., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio”) (NASDAQ: ASRT), a specialty pharmaceutical company offering...
Assertio (ASRT) has reported prelim net product sales of $49M-$50M (vs. $46.90M estimated) for its fourth quarter, representing an year-over-year growth of at least 54%
Here you can normally see the latest stock twits on ASRT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.